Back to Screener

Healthcare

Deciphera Pharmaceuticals, Inc.(DCPH)

Live Price

Offline

$25.59

+0.08% today

1Y Change

—

Window

No data

Market Cap
$2.21B
Revenue Growth
+21.9%
EPS Growth
+3.4%
Dividend Yield
0.0%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Deciphera Pharmaceuticals, Inc. (DCPH) is a Healthcare stock with a market cap of $2.21B. The stock last traded around $25.59. Baseline metrics include revenue growth of +21.9%, EPS growth of +3.4%, a dividend yield of 0.0%. What stands out right now is revenue +21.9%, EPS +3.4%, free cash flow +4.1% with operating margin -129.1% and ROIC -56.0%. Valuation already assumes a fairly strong business story at price/sales 13.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines DCPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+21.9% vs +7.6% peer median

Operating Margin

Below sector median

-129.1% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report landed above expectations

2024 was reported on May 10, 2024 with an EPS surprise of +5.5% and a revenue surprise of -2.8%.

The operating story is still moving forward

Revenue is running at +21.9% and EPS at +3.4%, with operating margin around -129.1%.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

DCPH

—

Normalized return

SPY

—

S&P 500

Excess Return

—

Relative to SPY

DCPH Max Drawdown

—

Trailing 1Y

SPY Max Drawdown

—

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for DCPH and SPY.

Calendar-year return history is still loading or unavailable.
DE

Company Overview

Deciphera Pharmaceuticals, Inc.

Last Updated
May 15, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
—
EV/EBITDA
—
Price/Sales
13.5
Price/Book
6.2

Growth

Revenue
+21.9%
EPS
+3.4%
Free Cash Flow
+4.1%

Profitability

Gross Margin
97.7%
Operating Margin
-129.1%
Net Margin
-119.3%
ROE
-56.3%
ROIC
-56.0%

Balance Sheet

Debt/Equity
0.07
Current Ratio
3.80

Earnings Reports

📅 Last reportedMay 10, 2024
PeriodB/MEPSEPS ΔRevenueRev Δ
—
May 10, 24
✓
-0.52
Est -0.55
+5.5%
44999.0B
Est 46280.0B
-2.8%
—
Feb 6, 24
✓
-0.54
Est -0.58
+6.9%
48294.0B
Est 45920.0B
+5.2%
—
Oct 30, 23
✓
-0.58
Est -0.60
+3.3%
43313.0B
Est 39350.0B
+10.1%
—
Aug 9, 23
✓
-0.57
Est -0.62
+8.1%
38304.0B
Est 35880.0B
+6.8%
—
May 3, 23
—
-0.60
Est -0.60
0.0%
33445.0B
Est 35800.0B
-6.6%
—
Feb 7, 23
✗
-0.60
Est -0.57
-5.3%
36345.0B
Est 35972.3B
+1.0%
—
Nov 3, 22
✓
-0.55
Est -0.57
+3.5%
35974.0B
Est 33082.3B
+8.7%
—
Aug 4, 22
✓
-0.60
Est -0.65
+7.7%
32494.0B
Est 30564.1B
+6.3%
—
May 4, 22
✓
-0.80
Est -0.84
+4.8%
29223.0B
Est 26875.2B
+8.7%
—
Feb 8, 22
✗
-1.51
Est -1.49
-1.3%
24199.0B
Est 23405.2B
+3.4%
—
Nov 2, 21
✗
-1.37
Est -1.29
-6.2%
23220.0B
Est 22600.0B
+2.7%
—
Aug 3, 21
✗
-1.21
Est -1.15
-5.2%
23573.0B
Est 23573.0B
0.0%
—
May 4, 21
✓
-1.06
Est -1.08
+1.9%
25156.0B
Est 21740.0B
+15.7%
—
Feb 9, 21
✓
-1.10
Est -1.16
+5.2%
19486.0B
Est 20333.2B
-4.2%
—
Nov 5, 20
✓
-1.13
Est -1.32
+14.4%
15449.0B
Est 9545.2B
+61.9%
—
Aug 4, 20
✓
-1.20
Est -1.34
+10.4%
7090.0B
Est 8094.4B
-12.4%

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks